This project investigates the safe and precise delivery of a stealth targeted nanocarrier system of trastuzumab (a monoclonal antibody that binds HER2 receptor outside the tumor cells) conjugated to nanoparticles encapsulating neratinib (a small molecule tyrosine kinase inhibitor that binds HER2 receptor inside the tumor cells) and docetaxel (a cytotoxic agent) for synchronized delivery and synergistic treatment of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.